echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Urol Focus: Interim oncological efficacy and patient-reported outcomes after local high-intensity focused ultrasound therapy for prostate cancer

    Eur Urol Focus: Interim oncological efficacy and patient-reported outcomes after local high-intensity focused ultrasound therapy for prostate cancer

    • Last Update: 2023-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multiparametric magnetic resonance imaging (mpMRI)/transrectal ultrasound (TRUS) fusion guided high-intensity focused ultrasound (HIFU) therapy is a local treatment
    for local prostate cancer (PCa) seen by MRI.
    High-quality evidence on its clinical efficacy remains limited
    .

     

     

    Recently, researchers from Germany published an article in the journal Eur Urol Focus investigating the medium-term oncology efficacy and patient-reported outcomes (PROMs)
    of HIFU.

     

     

    Studies were designed as prospective single-center cohort studies conducted from 2014 to 2020
    .
    The study included patients with an MRI/TRUS fusion and systemic prostate biopsy, ISUP grading (GG) ≤2, and a prostate-specific antigen (PSA) < of 10 ng/ml
    .
    The intervention studied was local HIFU therapy guided by MRI/TRUS fusion
    .
    The primary outcome of the study was the cancer-free rate
    of lesion biopsy after 1 year of HIFU treatment.
    Secondary endpoints included survival without treatment (STFS), survival without metastasis (MFS), overall survival (OS), and PROMs
    recommended by the International Federation for Health Outcome Measurement.

     

    A total of 50 patients (median [range] age 68 [48 to 80] years; median PSA 6.
    5 [1.
    2-9.
    9] ng/ml; GG1:54% [n=27],GG2:46% [n=23])
    。 From baseline to month 12, the median (range) decline in PSA was 51% (35.
    9-72.
    7%)
    .
    Overall, 37/50 patients (74%) received biopsies
    after 1 year.
    23 patients (46%; GG1:20% [n=10]; GG >1:26% [n = 13]; infield 40% [n = 20]) discovered PCa
    .
    At a median follow-up of 42 (13-73) months, PCa
    was detected in 30 men (60%).
    Of all patients, 19 (38%) received salvage therapy (median [95% confidence interval] STFS 53 [44.
    3 to 61.
    7] months).

    MFS and OS are 100% and 98%,
    respectively.
    The extended EPCI-26 sexual function score decreased by 20.
    8 points (P=0.
    372).

     

    Imaging and biopsy results after 1 year of HIFU treatment

     

    In summary, after 1 year of MRI/TRUS-guided local HIFU therapy, only half of the treated patients can completely ablate the tumor, and there will be recurrence at medium-term follow-up, and some patients have decreased
    efficacy.

     

    Original source:

    Niklas Westhoff , Ramona Ernst, Karl-Friedrich Kowalewski et al.
    Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial.
    Eur Urol Focus.
    Nov 2022

     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.